Management of Spironolactone in Cirrhotic Patients

Primary Reasons for Discontinuation

The American Association for the Study of Liver Diseases recommends stopping spironolactone due to hyperkalemia (potassium >5.5 mEq/L), worsening renal function (creatinine >2.5 mg/dL), or severe hyponatremia (sodium <120-125 mmol/L) in cirrhotic patients with ascites 1, 2
Patients with underlying parenchymal renal disease (diabetic nephropathy, IgA nephropathy) tolerate less spironolactone due to hyperkalemia 1
Risk factors that make hyperkalemia more likely include: baseline creatinine >1.6 mg/dL, baseline potassium >5.0 mEq/L, concomitant ACE inhibitors or NSAIDs, diabetes, elderly age, and dehydration 2

The American College of Gastroenterology recommends stopping spironolactone immediately if creatinine rises to >3.5 mg/dL (310 μmol/L) 2
If creatinine reaches 2.5 mg/dL (220 μmol/L), the spironolactone dose should be halved 2
The drug is contraindicated when creatinine clearance falls below 30 mL/min 2

Diuretics should be reduced or stopped when serum sodium drops below 120-125 mmol/L 1, 2, 4
Severe hyponatremia warrants fluid restriction and diuretic adjustment 4

Diuretics should be reduced or stopped if hepatic encephalopathy develops, as spironolactone can precipitate impaired neurological function and worsening encephalopathy in patients with cirrhosis and ascites 3

NSAIDs or COX-2 inhibitors are absolute contraindications to aldosterone antagonist use 2

If ascites persists despite maximum doses (spironolactone 400 mg + furosemide 160 mg), the patient has refractory ascites and should transition to large-volume paracentesis with albumin replacement (8g per liter removed) 2
In diuretic-resistant patients with tense ascites, serial paracentesis becomes more appropriate than continuing ineffective diuretic therapy 4